Company
Liquidia Corporation
Headquarters: Morrisville, NC, United States
Employees: 51
CEO: Dr. Roger A. Jeffs Ph.D.
Market Cap
$1.04 Billion
USD as of July 1, 2025
Liquidia Corporation Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $14.1 M |
| EBITDA | $-126,359,000 |
| Gross Profit TTM | $8.2 M |
| Profit Margin | 58.00% |
| Operating Margin | -1135.42% |
| Quarterly Revenue Growth | 5.00% |
Stocks & Indices
Liquidia Corporation has the following listings and related stock indices.
Stock: NASDAQ: LQDA wb_incandescent